Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled
JAMA Cardiol. 2022; online ahead of print DOI: 10.1001/jamacardio.2022.2924
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been found to reduce urine albumin-to-creatinine ratio (UACR) in patients with type 2 diabetes, but their effect in patients with heart failure (HF) is less well studied.
Using data from the EMPEROR-Pooled analysis, which included data from the EMPEROR-Reduced and EMPEROR-Preserved HF trials, the effect of empagliflozin on study outcomes was assessed across baseline levels of albuminuria. The association of empagliflozin with cardiovascular death or HF hospitalisation was consistent across UACR categories. Treatment with empagliflozin was associated with lower incidence of new macroalbuminuria and an increase in rate of remission to sustained normoalbuminuria or microalbuminuria. A reduction in UACR over time was not seen with empagliflozin in the overall population; however, UACR was reduced in patients with diabetes, who had higher UACR levels than patients without diabetes.